Immunome, Inc. (IMNM) and Zentalis Pharmaceuticals, Inc. (ZNTL) have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate which is on track for IND submission in first quarter 2025, and Zentalis' ADC platform technology.
"This agreement strengthens Immunome's pipeline while expanding our ADC toolbox," said Clay Siegall, Chairman and CEO of Immunome.
Zentalis will receive an up-front payment of $35 million in cash and Immunome stock. Zentalis will be eligible to receive up to $275 million of milestone payments in addition to mid-to-high single-digit royalties.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.